German science and technology group Merck has flown about 30 of its senior global executives to China for a new leadership program aimed at helping them draw on the country's innovation and talent in its worldwide operations, company executives said.
Participants were selected from Merck's top 100 leaders for the first China pilot program for alumni of Merck University, its senior leadership development program. Developed in partnership with business school Insead, the pilot started on Nov 16 and runs through Nov 20 in Beijing and Shanghai, combining academic sessions with visits to companies and research institutions.
Academics from Tsinghua University are also participating, according to the company.
Rogier Janssens, president of Merck China, said the program would examine capabilities ranging from academic research to expanding manufacturing capacity, giving executives a broader understanding of China beyond its role as a sales market.
Khadija Ben Hammada, an executive board member and chief people officer at Merck Group, said the aim was to bring its global leaders closer to Chinese teams and give them firsthand knowledge of the country's potential.
"When our global leaders understand China, they will consider China in the decisions they will make," she told China Daily.
China is Merck's second-largest market after the United States, and the company has invested about 7 billion yuan ($1 billion) in the country over the past decade, according to the company.
Janssens said the country's role in the company's business had changed since he first arrived in 2017 to lead its healthcare operations. He held that role until 2022 and returned this year as president of Merck China.
"When I came, we were like a multinational company bringing innovation to China, while today, I think it's much more a mutual process of us learning from China and China bringing innovation to the world," he said.
Janssens cited pimicotinib, a drug developed by Chinese biotechnology company Abbisko Therapeutics and licensed to Merck, as an example. The medicine treats tenosynovial giant cell tumors which are rare, noncancerous and affect joints.
In March 2025, Merck exercised an option to extend its commercialization rights worldwide for a fee of $85 million.
The original agreement, signed in 2023, gave Merck commercialization rights in China.
The US Food and Drug Administration approved the drug on Nov 10 for adults with symptomatic disease for whom surgery could cause serious complications or further impair physical function.
Such partnerships require Merck's Chinese and global teams to work closely together, Janssens said.
The heads of its healthcare, life science and electronics businesses in China participate in global decision-making, allowing them to raise local product and process needs directly, he said.
Merck is also strengthening those connections through short-term overseas assignments for Chinese employees, Ben Hammada said.
Some were already working outside China, sharing their expertise while gaining experience in other markets.
Successful practices have been brought from China back to Germany, she said, citing the speed with which Chinese teams put ideas into practice and tried new approaches when something did not work.
Janssens said the lesson was to learn more quickly, including from approaches that did not work.
"China speed is not only moving faster or running faster; it is also learning faster," he said.
